The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
“It’s time to pull back the curtain on pharmacy benefit managers and how their practices negatively impact patients,” said Russell Kridel, MD, a member of the AMA board of trustees, in a statement announcing adoption of the policy. “How is it that PBMs and health plans profit from negotiated discounts on prescription drugs while patients pay co-pays based on high drug list prices that even the plans themselves are not paying? Because of market concentration and lack of transparency, patients and physicians are essentially powerless in the face of PBM pricing and coverage decisions,” he added.
According to the AMA, PBMs have similar roles to insurers, yet face no similar oversight, and are hampering policymakers’ efforts to reduce drug costs with their “byzantine” confidential contracts that drive increased costs for drugs without justification.
The new policy calls for active regulation of PBMs by state departments of insurance, application of rebates to drug prices at the point of sale, efforts to ensure that no patients are discriminated against in benefit design, and increased transparency in how direct and indirect remuneration fees are calculated.
AMA also calls for increased PBM transparency, including disclosure of information on topics like rebates, discounts, and utilization; pharmacy and therapeutics committee information; and formulary information, which AMA says should be made available to patients and prescribers at the point of care.
AMA says that it will develop model legislation addressing state-level regulation of PBMs for policymakers to use.
In addition to its attempt to promote policy solutions, the AMA also seeks to get patients involved; the organization’s new policy is linked with AMA’s TruthinRx campaign, a resource for patients to learn about what influences the price of drugs, how drug prices for products like insulin are increasing over time despite competition, and the role of PBMs in negotiating discounts and rebates with drug makers.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.